3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com

December 4, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E. Washington, D.C. 20549

Attention:Jimmy McNamara and Laura Crotty, Office of Life Sciences

Re:	GRI Bio, Inc.
	Registration Statement on Form S-3
	Submitted October 13, 2023
	File No. 333-274972

Ladies and Gentlemen:

We are submitting this letter on behalf of GRI Bio, Inc. (the “Company”) in response to a comment from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) received by letter dated November 21, 2023 (the “Comment Letter”) from the Division of Corporation Finance, Office of Life Sciences, to Leanne Kelly, Chief Financial Officer of the Company, relating to the above-referenced registration statement. In conjunction with this letter, the Company is confidentially submitting its Pre-Effective Amendment No. 1 to its draft registration statement on Form S-3 on Form S-1 with the Commission.

For reference, we have set forth below in italics the Staff’s comment from the Comment Letter and have keyed the Company’s response to the numbering of the comment and the heading used in the Comment Letter. The response is based on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company.

Amendment No. 1 to Draft Registration Statement on Form S-3

General

Comment 1: We note that on April 21, 2023, GRI Bio, Inc. completed its merger with Vallon Pharmaceuticals, Inc. We further note that on August 22, 2023, the combined company entered into an Asset Purchase Agreement wherein Vallon’s legacy assets were acquired by Aardvark Therapeutics, Inc. Given these circumstances, please tell us your basis for registering this transaction on Form S-3. See Use of Form S-8, Form 8-K, and Form 20-F by Shell Companies, Release No. 33-8587 (July 15, 2005) at n. 32 as reiterated in Special Purpose Acquisition Companies, Shell Companies, and Projections, Release No. 33-11048 (March 30, 2022) at n. 239 and accompanying text. Alternatively, please amend your registration statement to register the offering on Form S-1.

Response 1:

The Company has filed its Pre-Effective Amendment No. 1 to its draft registration statement on Form S-3 on Form S-1.

BOSTON       LOS ANGELES       MIAMI       NEW YORK       SAN DIEGO       SAN FRANCISCO       TORONTO       WASHINGTON

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

MINTZ December 4, 2023 Page 2

We hope that the above response will be acceptable to the Staff. Please do not hesitate to call me at (858) 314-1873 with any comments or questions regarding the proposed disclosure. We thank you for your time and attention.

Sincerely,

/s/ Melanie Levy

Melanie Levy

cc:	GRI Bio, Inc.
	W. Marc Hertz, Ph.D.
	Leanne Kelly
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	Adam Lenain
	Jason Miller